Editorial

119 A New Era in System ic Therapy for Hepatocellular Carcinoma:Atezolizum ab plus Bevacizumab Com bination Therapy Kudo,M.(Osaka-Sayama))

Meta-Analysis

138 Comparison of Partial Hepatectomy and Transarterial Chem oembolization in Intermediate-Stage Hepatocellular Carcinoma:A Systematic Review and Meta-Analysis Labgaa,I.;Taffé,P.;Martin,D.;Clerc,D.(Lausanne);Schw artz,M.(New York,NY);Kokudo,N.(Tokyo);Denys,A.;Halkic,N.;Demartines,N.;Melloul,E.(Lausanne)

Original Papers

148 Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatm ent for Advanced Hepatocellular Carcinoma Patients Uchikawa,S.;Kaw aoka,T.;Namba,M.;Kodama,K.;Ohya,K.;Morio,K.;Nakahara,T.;Murakami,E.;Tsuge,M.;Hiramatsu,A.;Imamura,M.;Takahashi,S.;Chayama,K.;Aikata,H.(Hiroshima)

156 Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcom e in Multiple Hepatocellular Carcinoma:Reappraisal of the American Joint Com mittee on Cancer Staging System and Validation Using the Surveillance,Epidemiology,and End-Results Database Shindoh,J.;Kobayashi,Y.;Kaw amura,Y.;Akuta,N.;Kobayashi,M.;Suzuki,Y.;Ikeda,K.;Hashimoto,M.(Tokyo)

167 Developm ent of a Novel Infl amm ation-Based Index for Hepatocellular Carcinoma Chan,S.L.(Hong Kong);Wong,L.-L.(Newcastle upon Tyne);Chan,K.-C.A.;Chow,C.;Tong,J.H.-M.;Yip,T.C.-F.;Wong,G.L.-H.;Chong,C.C.-N.(Hong Kong);Liu,P.-H.(Dallas,TX/Taipei);Chu,C.-M.;Wong,V.W.-S.;To,K.-F.(Hong Kong);Reeves,H.L.(Newcastle upon Tyne);Chan,A.W.-H.(Hong Kong)

182 Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma:Different Approach w ith a Predictive Biom arker Kim,C.M.(Daejeon);Hwang,S.;Keam,B.(Seoul);Yu,Y.S.(Daejeon);Kim,J.H.;Kim,D.-S.;Bae,S.H.(Seoul);Kim,G.-D.(Daejeon/Busan);Lee,J.K.;Seo,Y.B.(Daejeon);Nam,S.W.(Incheon);Kang,K.J.(Daegu);Buonaguro,L.(Naples);Park,J.Y.(Daejeon);Kim,Y.S.(Incheon);Wang,H.J.(Suw on)

193 Skeletal Muscle Mass Infl uences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated w ith Lenvatinib Uojima,H.(Sagamihara/Kamakura);Chuma,M.(Yokohama);Tanaka,Y.;Hidaka,H.;Nakazawa,T.(Sagamihara);Iwabuchi,S.(Fujisawa);Kobayashi,S.(Yokohama);Hattori,N.(Kaw asaki);Ogushi,K.;Morimoto,M.(Yokohama);Kagaw a,T.(Isehara);Tanaka,K.(Hadano);Kako,M.(Kamakura);Koizumi,W.(Sagamihara)

207 Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifi es Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients w ith Oral Antiviral Therapy Tseng,T.-C.(Taipei);Peng,C.-Y.(Taichung);Hsu,Y.-C.(Kaohsiung);Su,T.-H.(Taipei);Wang,C.-C.(Taipei/Hualien);Liu,C.-J.;Yang,H.-C.;Yang,W.-T.(Taipei);Lin,C.-H.(Taichung);Yu,M.-L.(Kaohsiung);Lai,H.-C.(Taichung);Tanaka,Y.(Nagoya);Nguyen,M.H.(Palo Alto,CA);Liu,C.-H.;Chen,P.-J.;Chen,D.-S.;Kao,J.-H.(Taipei)

Letters to the Editor

221 Comprehensive Consideration before the Decision-Making of the Systemic Treatm ent in Patients w ith Advanced Hepatocellular Carcinom a Chen,M.;Hu,J.;Cao,J.;Cai,X.(Hangzhou)

223 Response to the Com ments on Rim assa et al.:“Systemic Treatm ent Options in Hepatocellular Carcinoma”Rimassa,L.;Pressiani,T.(Rozzano(Milan));Merle,P.(Lyon)

225 Synthetic Lethality Is a Novel and Potential Paradigm for Precision Medicinein Advanced Hepatocellular Carcinom a Chen,M.;Cai,X.(Hangzhou)

227 APPLENew s